22-Jan-2021 - Forbion Capital Partners

Development of a small molecule that inhibits the replication of SARS-CoV-2 and other RNA viruses

Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics

Forbion, a European life sciences venture capital firm, announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc., a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses.

CoviCept’s lead molecule has a unique mechanism of action that is based on interference of a host cell protein and is therefore expected to have a low risk of viral resistance. It has been demonstrated to inhibit SARS-CoV-2 replication in a relevant mammalian model at a clinically relevant dose. A manufacturing process for the lead compound has been established and it has demonstrated good bioavailability and safety in humans in phase 1 studies.

CoviCept was founded by Sam Tsimikas, Philip Gordts and Jeffrey Esko, all from the University of California San Diego. The Company’s aim is to initiate a first clinical study in the second half of 2021.

Professor Tsimikas, Co-Founder, Chairman and Chief Executive Officer of CoviCept, commented: “We are pleased that Forbion has invested in us to support our continued development of a much-needed direct therapeutic option to the COVID-19 pandemic, and other RNA viruses. Forbion will provide the necessary financial and management support to allow the Company to achieve Phase 2 proof of concept data. Forbion’s track record and expertise in supporting the development of early-stage companies make them the ideal partner for CoviCept.”

Sander van Deventer, Operating Partner of Forbion, added: “Our investment in CoviCept is an example of Forbion’s commitment to responsible drug development. RNA viruses such as SARS-CoV-2, SARS-CoV-1, MERS-CoV, Ebola, Dengue, Chikungunya and Zika are the most likely cause of future pandemics. A small molecule like CoviCept’s, that can be stockpiled to be immediately available and that could be used in multiple viruses, is of enormous benefit to global health.”

The board of directors of CoviCept will comprise Sam Tsimikas, Philip Gordts, Jeffrey Esko and Sander van Deventer (Forbion).

Facts, background information, dossiers
  • investments
  • seed financing
  • small molecules
  • RNA viruses
More about Forbion Capital Partners
  • News

    Forbion Closes Oversubscribed Fourth Life Sciences VC Fund at EUR 360 million

    Forbion has announced the final close of its new flagship fund, Forbion IV. The oversubscribed fund closed at EUR 360 million in capital commitments, significantly above its original target of EUR 250 million. Forbion IV, like its predecessor fund, Forbion III, will primarily focus on oppo ... more

    Bristol-Myers Squibb enters agreement to acquire Promedior, Inc.

    Bristol-Myers Squibb Company and Promedior, Inc. announced that the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase ... more

    Closing of public offering of Argos Therapeutics

    Forbion Capital Partners announces that its portfolio company Argos Therapeutics has closed its initial public offering. The initial public offering price was $8.00 per ordinary share. Argos' ordinary shares have listed on the NASDAQ Global Market and began trading under the symbol "ARGS" o ... more